Precipio is a healthcare biotechnology company that combines clinical laboratory services with proprietary diagnostic product development to improve cancer diagnostics, particularly for hematologic malignancies. The company operates two complementary divisions: a Pathology Services Division that provides specialized cancer diagnostic testing to physicians and hospitals across multiple states while serving as a self-funded R&D engine, and a Products Division that develops and commercializes proprietary diagnostic assays for use by other clinical laboratories. Its core offerings include HemeScreen, a suite of disease-specific genetic diagnostic panels using RT-PCR technology, and IV-Cell, a proprietary universal cell culture media for cytogenetics workflows; the company generates revenue through laboratory service fees billed to Medicare, Medicaid, private insurers, and managed care entities, as well as through direct or distributor sales of research-use-only diagnostic products to laboratories.